Royalty Pharma is the largest buyer of biopharmaceutical royalty interests and a leading funder of innovation across the biopharma industry. We play an important role in providing capital to the biopharma ecosystem and thereby positively impact human health. Our sustainability efforts reflect the uniqueness of our business model. Despite the passive nature of our business, we strive to invest in novel therapies that address unmet patient needs and support ethical business practices that drive innovation, competition, and patient choice.